Astrana Health Q2 Revenue Jumps 49% to $972.5M, but Lingering Material Weakness Tempers the Quarter

summarizeSummary

Astrana Health posted strong Q2 2026 results with revenue up 49% to $972.5M and net income more than doubling, but an unremediated material weakness in internal controls remains a key risk.

check_boxKey Events · Earnings and Guidance · ASTH

• Q2 Revenue Surges 49%

  Revenue reached $972.5 million, up 49% year-over-year, primarily from the Prospect acquisition which contributed $281.5 million in the quarter.

• Net Income More Than Doubles

  Net income attributable to Astrana was $19.7 million, up 109% from $9.4 million a year ago, with adjusted EBITDA of $68.9 million.

• Material Weakness Remains Unremediated

  The material weakness in internal control over financial reporting related to business combination accounting, first disclosed in the 2025 10-K, has not been remediated. Disclosure controls and procedures are not effective as of June 30, 2026.

• Prospect Purchase Accounting Finalized

  The purchase price allocation for the Prospect acquisition was finalized, resulting in a $20.2 million increase in assumed liabilities and goodwill of $887 million.

auto_awesomeAnalysis · ASTH · Trade & Services

Astrana Health delivered strong Q2 2026 results, with revenue climbing 49% year-over-year to $972.5 million and net income more than doubling to $19.7 million, largely fueled by the Prospect acquisition. Yet a significant governance red flag tempers the otherwise solid operational performance: the company disclosed that a material weakness in internal control over financial reporting related to business combination accounting remains unremediated, and its disclosure controls are not effective. The balance sheet offers ample liquidity, with $400.8 million in cash and total debt reduced to $948.3 million. Finalizing the purchase price allocation for Prospect added $20.2 million in assumed liabilities, pushing goodwill to $887 million.